Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 14, 2018
Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting
MONTPELLIER, France, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sensorion (ALSEN.PA), a biotech company specializing in the treatment of inner ear diseases, today announces new data ...
February 14, 2018
Galmed Announces ARRIVE Study Data
TEL AVIV, Israel, Feb. 14, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the ...
February 14, 2018
DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics
CUPERTINO, Calif., Feb. 14, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that its licensee, Pain Therapeutics (PTIE), reported yesterday that it has resubmitted the ...
February 14, 2018
Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the expansion of its Scientific Advisory Board ...
February 14, 2018
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
RA’ANANA, Israel and NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
February 13, 2018
Heron Therapeutics to Present at the 7th Annual Leerink Partners Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient ...
February 13, 2018
Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial
IRVING, Texas, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today announced results from the long-term ...
February 13, 2018
Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, today announced that Dr. Christine Esau, Senior Director ...
February 13, 2018
Moberg Pharma AB Year-end Report 2017
STRONG GROWTH FOR KERASAL NAIL INCREASES EBITDA STOCKHOLM, Feb. 13, 2018 /PRNewswire/ -- PERIOD (FULL YEAR 2017)* Net revenue SEK 439.0 million (334.3) EBITDA SEK ...
February 13, 2018
Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Webcast Scheduled for February 28
REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
February 13, 2018
BioLife Solutions Executes OEM Agreement with MilliporeSigma
BOTHELL, Wash., Feb. 13, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media ("BioLife" or ...
February 13, 2018
Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2017 Financial Results on February 27, 2018
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant ...
February 13, 2018
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization Application ...
February 13, 2018
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
February 12, 2018
BioCanCell Presents Final Data from Its Phase 2 Study of BC-819 for Early Stage Bladder Cancer at the 2018 ASCO Genitourinary Cancers Symposium
CAMBRIDGE, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies ...
February 12, 2018
Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced financial results for its fiscal 2018 first quarter ended December 31, 2017. The company is hosting a ...
February 12, 2018
Neovasc to Present at LEERINK Partners 7th Annual Global Healthcare Conference
VANCOUVER , Feb. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that Fred Colen , President and Chief Executive ...
February 12, 2018
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
CRANBURY, N.J., Feb. 12, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases ...
February 12, 2018
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
ROCKVILLE, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
February 12, 2018
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced ...
Page 66 of 117